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Incubation of actin with decavanadate induces cysteine oxidation and oxidovanadium(IV) formation.
The studies were performed combining kinetic with spectroscopic (NMR and EPR) methodologies.
Although decavanadate is converted to labile oxovanadates, the rate of deoligomerization can be very
slow (half-life time of 5.4 h, at 25 ◦C, with a ﬁrst order kinetics), which effectively allows decavanadate
to exist for some time under experimental conditions. It was observed that decavanadate inhibits
F-actin-stimulated myosin ATPase activity with an IC50 of 0.8 mM V10 species, whereas 50 mM of
vanadate or oxidovanadium(IV) only inhibits enzyme activity up to 25%. Moreover, from these three
vanadium forms, only decavanadate induces the oxidation of the so called “fast” cysteines (or exposed
cysteine, Cys-374) when the enzyme is in the polymerized and active form, F-actin, with an IC50 of
1 mM V10 species. Decavanadate exposition to F- and G-actin (monomeric form) promotes vanadate
reduction since a typical EPR oxidovanadium(IV) spectrum was observed. Upon observation that V10
reduces to oxidovanadium(IV), it is proposed that this cation interacts with G-actin (Kd of 7.48 ±
1.11 mM), and with F-actin (Kd = 43.05 ± 5.34 mM) with 1:1 and 4:1 stoichiometries, respectively, as
observed by EPR upon protein titration with oxidovanadium(IV). The interaction of
oxidovanadium(IV) with the protein may occur close to the ATP binding site of actin, eventually with
lysine-336 and 3 water molecules.
1. Introduction
It has been recently reviewed that biological effects of vanadium
are not exclusively due to monomeric vanadate or vanadyl
(oxidovanadium(IV)) cation, but also to other oxovanadate forms
such as decameric vanadate species.1 This oxovanadate species,
also referred to as decavanadate (V10), is known to affect li-
pidic structures, protein function and also several biochemical
processes.2 One of these processes is the formation of F-actin, the
major component ofmuscle thin ﬁlaments, is shown tobe inhibited
by decavanadate with an IC50 of 17 mM, whereas no effects were
detected for monomeric vanadate species.3 These studies were
further explored and the results described in the present paper.
The chemistry of vanadium is characterised by multiple oxi-
dation states (+2 to +5), being mostly found in the +4 and +5
states, both of which are readily accessible under physiological
conditions.4 At low pH the V(IV) species (oxidovanadium(IV)
cation) are more favored, whereas at high pH V(V) (vanadate
anions) is the most stable form of vanadium in aqueous solution.5
Around neutral pH, V1 (H2VO4- and HVO42-) condenses with
itself to form dimeric (V2), tetrameric (V4) and pentameric (V5)
structures.6,7 Upon acidiﬁcation of neutral solutions (from pH 2
to 6) a decameric vanadate species (V10O286-) is formed. This
vanadate species V10 is responsible for the yellow/orange colour of
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vanadate solutions and is thermodynamically unstable at neutral
and alkaline pH values. This oxoanion contains three different
types of vanadium atoms, the most unusual being the VO6-
type observed for the two central vanadium atoms.5 Besides
pH, both vanadate concentration and ionic strength can also
account for the different states of protonation and structures
observed for the different oligomeric vanadate species that occur
simultaneously in equilibrium.7–9 The blue oxidovanadium(IV)
cation (VO2+) undergoes autoxidation to the colourless vanadate
(H2VO4-) in the presence of oxygen, whereas vanadate, in turn,
can be reduced by reductants such as glutathione, ascorbate,
NADPH10 or cysteine,11 whereas it has also been described that
decavanadate reduction does not necessarily imply the disruption
of the molecular structure.12
Oxidovanadium(IV) cation binds tightly to various pro-
teins including serum albumin, carboxypeptidase, nucleases
and phosphatases.4,13 Vanadate species associate randomly with
proteins such as the E1E2-ATPases,1,14 phosphofructokinase,15
transferrin,16 ribonucleases1,17 among many others.1,4 Most studies
about the interactions/effects of vanadate with proteins consid-
ered monomeric vanadate as the active species.1,4,8 However, in
the last 10 years the number of studies involving decavanadate
has increased gradually.1 In fact, V10 has proved itself to be a very
useful tool in the comprehension of protein structure and function,
biochemical mechanisms and biological processes,18–22 being now
considered the major protein-bound vanadate species.1,22 More-
over, it is known that decavanadate interacts with enzymes at
the polyphosphate, nucleotide and inositol-3-phosphate binding
sites in the substrate domain or in an allosteric site, in a complex
manner.1
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The connection between vanadium and muscle contraction
started when it was discovered that vanadium in horse-muscle-
derived ATP inhibited sodium/potassium pump activity23 and
since then many studies have been perfomed linking vanadium
and vanadium complexes with proteins involved in the mechanism
and regulation of muscle contraction.1,3,9,24 One of the major
proteins of the contractile protein group is actin. Monomeric actin
(G-actin) polymerizes to formF-actin, themajor component of the
thin ﬁlament of the contractile system. In muscle cells, this poly-
merization process is essential for contraction because G-actin,
by itself, does not stimulate myosin ATPase activity. Previous
studies from Combeau and Carlier25 demonstrate that vanadate,
upon binding to F-actin-ADP subunits, increases the strength of
actin–actin interactions in the ﬁlament in a phosphate-like fashion.
It has been reported that vanadate stabilizes F-actin ﬁlaments
through the formation of F-actin-ADP·V1 complexes and induces
actin polymerizationby inhibiting speciﬁc tyrosine phosphatases.26
However, vanadate concentrations in the millimolar range favour
the appearance of vanadate oligomers such as tetrameric vanadate
species, and could induce changes in protein structure and
function, and eventually destabilize the structure of the ﬁlament,
whichwas also suggested byRamos et al.3 These authors proposed
that besides V4 species, the presence of V10 strongly induces F-actin
depolymerization and G-actin polymerization inhibition, whereas
no effects were observed for metavanadate solutions up to 2 mM,
that contain mostly monomeric vanadate species but not V10
species.Moreover, it was also demonstrated thatV10 becomesmore
stable upon interaction with G-actin.3
In the present paper, it was observed that only decameric species
induce oxidation of cysteines from actin, probably through a
process that involves the reduction ofV10 to oxidovanadium(IV). It
is proposed that this redox behaviour of V10 might be responsible,
at least in part, for the described inhibition of the myosin-
S1-ATPase stimulated by F-actin exposured to decavanadate.
Although it is not possible to determinewhich oxovanadate species
or vanadium atoms undergo reduction, the effect is only observed
in the presence of decavanadate.
2. Material and methods
2.1 Protein puriﬁcation
Actin was extracted from acetone powder of rabbit skeletal muscle
in a medium containing 2 mM Tris, pH 8.0, 0.2 mM ATP,
0.2 mM CaCl2, 0.5 mM b-mercaptoethanol, and 0.005% NaN3,
as described by Pardee and Spudich.27 G-actin (Mr 42.3 kDa)
concentration was determined by measuring the absorbance at
290 nm using an extinction coefﬁcient of 0.617 mg-1 mL cm-1.28
Myosin subfragment-1 (S1) was prepared from leg and dorsal
rabbit skeletal muscle and obtained by chymotryptic digestion
as indicated in Tiago et al.9 S1 (Mr 115 kDa) concentration
was determined spectrophotometrically by using an extinction
coefﬁcient of e1%280 = 7.5 cm-1.
2.2 Preparation of “metavanadate”, “decavanadate” and vanadyl
solutions
Metavanadate solutions (50 mM, pH 6.0–7.0) were prepared from
ammonium metavanadate (NH4VO3). Decavanadate solutions
were obtained by adjusting the pHof themetavanadate solution to
4.0.14,29 The presence of decameric vanadate species was revealed
by a characteristic orange color. Decavanadate solutions were
always adjusted to pH 7.5 immediately before using. Vanadyl
solution (50 mM) was obtained from vanadyl sulfate (VOSO4)
in anaerobic conditions using a glove box. Wherever possible,
vanadium(IV) and (V) solutions were added to the assays from
the concentrated or from a 10-fold dilution of the stock solutions.
All the solutions were kept at 4 ◦C.
2.3 UV-Visible characterization of decavanadate solutions
The kinetics of decameric species dissociation was determined
from measurements of the absorption at 400 nm (an absorption
band which is characteristic of decameric vanadate), using a
HP 8452A diode array spectrophotometer. The reactions were
started after addition of 1 mM decavanadate solution (100 mM
of decameric vanadate species) to the reaction medium (2 mM
Tris, pH 7.5, in the presence or absence of 0.2 mM CaCl2
and 0.2 mM ATP). The kinetics were followed for 120 min at
different temperatures. Since the V10 dissociation follows a ﬁrst-
order reaction kinetics,29 it was possible to determine the activation
energy (Ea) for the dissociation.
2.3 51V NMR measurements
51V NMR spectroscopy measurements were performed on a
Bruker AM-400 MHz spectrometer at 105.2 MHz equipped with a
5 mm multinuclear inverse probe. Spectra were acquired at 25 ◦C,
using 0.5 ml of samples containing 10% D2O, under the following
conditions: 90◦ pulse angle, spectral width 45 454 Hz, acquisition
time 0.086 s, number of transients between 12 000 and 25 000 and
a relaxation delay of 0.01 s. For comparative measurements all
the spectral parameters were kept constant. 51V NMR chemical
shifts are reported relative to an external reference, VOCl3 (0 ppm).
NMR spectra of metavanadate (2 mM) and decavanadate (5 mM)
solutions were obtained in 2 mM Tris (pH 7.5), 0.2 mM CaCl2,
in the absence or presence of ATP and ADP (2 mM), G- and
F-actin, as desired. The ionic strength effect was evaluated by
KCl addition (5 mM). The 51V NMR line widths of the several
free and bound vanadate resonances represent the widths at half-
height after subtraction of 20 Hz used in line broadening. The
concentrations of each vanadate species Vx were calculated from
the fractions of the total integrated areas using the following
equation: [V x] = (Ax/At) ¥ ([V t]/n), where Ax corresponds to the
area measured for the x vanadate species with n as the oligomer
number (number of vanadium atoms), At the sum of measured
areas, and [V t] the total vanadate concentration, according to that
described elsewhere.14,29
2.4 Measurements of F-actin stimulated S1-Mg2+-ATPase
activity
Actin samples (2 mM) were incubated with various concentrations
of meta-, decavanadate and sulfate vanadyl solutions at 25 ◦C
for 20 min, in 2 mM Tris (pH 7.5), 0.2 mM CaCl2 and 0.2 mM
ATP. The stimulation of myosin S1 Mg2+-ATPase activity by
F-actin was measured spectrophotometrically at 340 nm using the
coupled enzyme pyruvate kinase/lactate dehydrogenase (0.42 mM
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phosphoenolpyruvate, 0.375 mM NADH, 18 U of lactate dehy-
drogenase, and 18 U of pyruvate kinase), as in Tiago et al.9
2.5 Measurements of cysteine oxidation
The titration of actin cysteines was performed with DTNB, as
indicated previously,30,31 using an extinction coefﬁcient at 412 nm
of 10 900 M-1 cm-1 for the coloured product thionitrophenolate.
The assays were carried in 2 mM Tris (pH 7.5), 0.2 mM CaCl2, in
the presence or absence of 0.2 mM ATP, after 20 min of incubation
with meta- and decavanadate solutions.
2.6 Electron paramagnetic resonance spectroscopy
EPR spectra were carried out with a conventional X-band Bruker
EMX 6/1 spectrometer equipped with a Bruker ER4116DM dual
mode cavity. An Oxford ESR900 continuous-ﬂow cryostat was
used. The spectra of frozen solutions were acquired at 77 K using
0.2 ml of samples with vanadyl sulfate and G- or F-actin in 2 mM
Tris (pH 7.5), 0.2 mM CaCl2 ± 0.2 mM ATP as desired. All the
samples were prepared in a glove box and the solutions used were
always purged with nitrogen before using. Therefore, after being
prepared in anaerobic conditions, the samples were then closed
and frozen with nitrogen when taken out from the glove chamber.
Under these conditions, no oxidation is supposed to occur. NMR
could be used to analyze the vanadate formation but the sensitivity
is too low once mM concentrations of oxidovanadium(IV) were
used. Besides, the presence of paramagnetic species broadens
the NMR signals and decreases the signal/noise ratio. Upon
titration of oxidovanadium(IV) with protein, the EPR intensities
were determined from the transition peak of -1/2 perpendicular.
Contrary to the studies performed in the glove chamber, the
actin–vanadate reduction and subsequent oxidovanadium(IV)
formation was evaluated using samples prepared in the same
conditions of the cysteine oxidation measurements (2 mM Tris,
pH 7.5, 0.2 mM CaCl2 ± 0.2 mM ATP, incubation at 25 ◦C for
20 min, aerobic conditions). Typical measurement conditions for
CW-EPR were ﬁeld modulation frequency, 100 kHz; modulation
amplitude, 5 G; receiver gain, 2 ¥ 105; time constant, 40.96 ms;
sweep time 167.77 s; microwave power, 0.635 mW and the number
of scans, 4. For the simulation of EPR spectra the linewidths forG-
actin, were 20.0, 20.0, and 24.0 G, respectively for the x-direction,
y-direction and z-directionwhereas for F-actin: 22.2, 22.2 and 26.6
G were used. The lineshapes were Lorentzian/Gaussian for both.
3. Results and discussion
3.1 Decavanadate stability, characterization and interaction
with actin
The decomposition of decameric vanadate species in the buffers
used in the present study (2 mM Tris, pH 7.5, 0.2 mM CaCl2 plus
0.2 mM ATP, wherever indicated), was monitored at 400 nm, and
followed a ﬁrst-order kinetics (data not shown) in a temperature-
dependent manner: the rate of decavanadate hydrolysis is con-
siderably faster as the temperature is raised (k25 ◦C = 0.129 ±
0.006 h-1 and k45 ◦C = 0.769 ± 0.023 h-1), in agreement with that
described elsewhere.32,33 The presence of calcium or ATP in the
concentrations used in the assays did not change the decavanadate
rate of decomposition (data not shown). The activation energy,
Ea (ln k = Ea R-1 T-1, where k corresponds to the kinetic constant
at temperature T , in Kelvin, and R is the universal gas constant),
is about 63.4 ± 2.7 kJ mol-1 (Fig. 1). In other studies, in water and
in KCl/imidazole buffer, the Ea obtained was in the order of 94
and 97 kJ mol-1, respectively.32 The relatively high half-life time at
25 ◦C (ª 5.4 h) and the type of kinetics allows the analysis of the
interaction of decavanadate with actin even at relatively low total
vanadate concentrations (100 mM), that correspond to an even
lower (10 mM) decameric vanadate concentration.
Fig. 1 Decomposition of decavanadate at pH 7.5 and different tempera-
ture values. Decavanadate stock solution (50 mM) was diluted to the ﬁnal
concentration (1 mM total vanadate) at the start of the experiments in
2 mM Tris, pH 7.5, 0.2 mM CaCl2, 0.2 mM ATP. The ﬁrst-order reactions
were followed at 400 nm for 2 h.Data (solid squares) are plotted asmeans ±
SD. The results shown are the average of triplicate experiments.
As it has been described in previous studies, the 51V-NMR
spectroscopy of meta- and decavanadate solutions allows precise
quantiﬁcation of the amount of each vanadate species in the
assays.14,15,29 In fact, for the decavanadate concentration used
in the NMR studies (5 mM total vanadate), the spectrum
obtained (Fig. 2A) shows the characteristic signals of decameric
(V10A at -516 ppm; V10B at -502 ppm; V10C at -424 ppm) and
monomeric species (V1 at -561 ppm), containing approximately
480 mM V10 and 200 mM V1 (decameric vanadate is about
2.5-fold more concentrated than monomeric vanadate). Using
NMR spectroscopy, it is possible to determine the decameric
vanadate concentration, the presence of other vanadate oligomers
in solution, as well as speciﬁc interactions with proteins. With
total vanadate concentration in the mM range, V10 concentration
increases linearly with total vanadate concentration. However this
behaviour depends on vanadate oligomeric species.22 For instance,
a metavanadate solution (2 mM) contains 1 mM V1 (-561 ppm),
200 mM V2 (-567 ppm) and 120 mM V4 (-579 ppm), in equilibrium
(Fig. 2B) and each of this species does not increase linearly with
vanadate concentration, with the higher oligomers being favoured
at higher vanadate concentrations.
The addition of G-actin (40 mM) to a 5 mM decavanadate
solution (500 mM decameric species) has different effects on
the signals of the vanadate species, promoting the half-height
linewidth broadening of the decameric vanadate signal (V10A),
from 139 to 299 Hz (2.1-fold), whereas its intensity (peak height)
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Fig. 2 105.2 MHz 51V-NMR spectra, at room temperature, of (A) 5 mM decavanadate (total vanadate) and (B) 2 mM metavanadate in 2 mM Tris
(pH 7.5), 0.2 mM CaCl2. V1 and V2 NMR signals correspond, respectively, to monomeric (H2VO4-) and dimeric (HV2O73- and H2V2O72-) vanadate species
irrespective of the protonation state, V4 and V5 correspond to cyclic tetrameric (V4O124-) and pentameric (V5O135-) vanadate species, whereas V10A, V10B
and V10C signals correspond to the V(2), V(1) and V(3) vanadium atoms in the decameric vanadate species (V10O286-).
decreases (Fig. 3A and B). Conversely, no signiﬁcant changes
were detected in the NMR signal corresponding to monomeric
vanadate upon G-actin addition. By increasing the ionic strength
(addition of 100 mM KCl), a decrease in the half-height linewidth
of V10A signals, from 299 to 219 Hz upon addition of protein
was observed (1.5-fold), suggesting that the interaction between
decameric vanadate and the protein is affected (Fig. 3C and D).
Once the analysis of decameric vanadate versusG-actin interaction
is favoured at lower ionic strength, NMR studies were carried
out without further addition of salts to the assays’ medium
(2 mM Tris, pH 7.5, 0.2 mM CaCl2). In one of this set of
experiments, it was observed that the presence of high con-
centrations of ATP (5 mM) broadens the V10 signal (1.5-fold)
(Fig. 3E and F).
Upon titration of decavanadate with G-actin, in the absence
of any natural ligand (ATP), it was also observed that, at a
10:1 decavanadate ion:protein molecule ratio, the V10A signals did
not present further broadening when the protein concentration
increases (Fig. 4A). The G-actin concentration at which the
broadening factor is halfway between bottom (F = 0.91 ± 0.10)
and top (F = 2.23 ± 0.07) was 25.42 ± 2.32 mM, taking into account
the Boltzmann sigmoidal function used to ﬁt the data (Fig. 4A).
Fig. 3 105.2 MHz 51V-NMR spectra, at room temperature, of 5 mM decavanadate (total vanadate) in (A) 2 mM Tris (pH 7.5), 2 mM CaCl2 and with
(B) 40 mM G-actin, (C) 100 mM KCl, (D) solution C plus 40 mM G-actin, (E) 5 mM ATP, and (F) solution E plus 40 mM G-actin.
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Fig. 4 Decavanadate solution (5 mM total vanadate) titrated with (A)
G-actin in a medium containing 2 mM Tris (pH 7.5), 0.2 mM CaCl2; Data
(solid squares) are plotted as means ± SD and ﬁtted with a Boltzmann
sigmoidal function; and (B) F-actin in 2 mM Tris (pH 7.5), 0.2 mM CaCl2,
0.2 mM ATP. Broadening factor, F , represents the quotient between the
line width of the V10A signal in the absence of actin and after protein
addition. The results shown are the average of triplicate experiments. In
certain experimental conditions the error bar is within the diameter of the
symbol.
A similar experiment was conducted with the polymerized form
of actin, but the dispersion pattern could not be ﬁtted by any
mathematical function and therefore no kinetic constants could
be calculated (Fig. 4B). Note that in this graphic the error bars are
within the diameter of the symbols. This low error ofmeasurement,
in comparison to the above situation with the monomeric form of
actin, G-actin, is probably due to the viscosity of the polymerized
form of actin. We also cannot exclude that the ratio between
depolymerized/polymerized form of actin might be affected by
the monomeric concentration of G-actin, that will contribute to
a higher error of measurement of the width of the NMR signal
observed in the former situation in particular for lower G-actin
concentrations. Nevertheless, consistent with former studies,3,34
F-actin (40 mM) produced a broadening from 165 to 207 Hz
(1.3-fold) in the V10A NMR signal of the decameric vanadate
species (data not shown).
Table 1 pH effect in S1-ATPase (0.05 mg/ml) activity stimulated
by 2 mM F-actin treated with different decavanadate concentrations
([Decavanadate]stock = 5 mM), in 2 mM MES (pH 6.0) or 2 mM Tris
(pH 7.5), 0.2 mM CaCl2, 0.2 mM ATP, 2.5 mM MgCl2, at 25
◦C for
20 min. Quantiﬁcation by coupled enzymes assay.9 The results shown are
the average of triplicate experiments
Buffer pH IC50 (mM) (V10)
2 mM MES 6.0 0.52 ± 0.06
2 mM Tris 7.5 0.80 ± 0.15
3.2 Decavanadate inhibits F-actin stimulated S1-ATPase activity
Based on the above NMR observations, it is proposed that V10
NMR signals are affected upon actin interaction. This in turn
leads to the question: is the actin function affected by this vanadate
oligoanion? In order to clarify if decavanadate inﬂuences the actin
physiological function, that is, the ability to stimulate the myosin
ATPase activity during the process of muscle contraction, F-actin
(2 mM) was incubated with different vanadate, decavanadate and
oxidovanadium(IV) concentrations and its subsequent capacity to
stimulate myosin-S1-ATPase (0.05 mg/ml) activity was analyzed
(Fig. 5). It was observed that while metavanadate and oxidovana-
dium(IV) solutions promote no more than 25% inhibition for the
maximum vanadium concentration used (50 mM), decavanadate,
in turn, is a stronger inhibitor, preventing the ability of F-actin
to stimulate S1-ATPase with an IC50 = 8.04 ± 1.49 mM total
vanadate, i.e. 0.80 ± 0.15 mM for decameric vanadate species. Since
HV10O285- has a pKa value of 6.14, the assays were also performed
at pH6.0 (2mMMES, 0.2mMCaCl2, 0.2mMATP) and an IC50 =
0.52 ± 0.06 mM for V10 was also determined (Table 1). Therefore,
HV10O285- and V10O286- ions seem to have similar inhibitory effects
in the actin stimulation of myosin ATPase activity.
3.3 Actin cysteine oxidation versus decavanadate reduction
If decameric vanadate affects the ability of actin to stimulate the
myosin ATPase activity, this effect could be due to changes in
the structure of actin that would be responsible for the blockage
of myosin stimulation. On the other hand, decavanadate could
affect the myosin ATPase activity itself. This second hypothesis
has already been answered, since it was suggested that decameric
vanadate behaves as a back-door myosin inhibitor.9,22 Regarding
the changes in actin structure, it is known that disulﬁde bonds are
important in the stabilization of protein structure and that thiol
groups, located near the active center of enzymes for instance, are
essential in the function of many enzymes. Therefore, since actin
contains ﬁve cysteines that could react with vanadate, cysteine
oxidation in the presence of vanadate was analyzed.
It was observed that after an exposure of 20 min to two different
vanadate solutions, metavanadate and decavanadate, only the
solution containing V10 was able to oxidize one of the G-actin
core cysteine residues, with an IC50 = 7.8 ± 0.2 mM decavanadate
(0.78 mM ± 0.02 V10), while the only exposed residue (Cys-
374), the so called “fast cysteine”, remains in its reduced form
(Fig. 6A). When ATP is present in the medium all ﬁve cysteine
residues still maintain the reduced form (data not shown) upon
exposure to decavanadate, suggesting that V10 interaction with
actin is affected by ATP, as previously described using NMR
spectroscopy.3 However, upon decavanadate incubation with
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Fig. 5 Effect of F-actin incubation with V(IV) and V(V) on stimulation of S1 ATPase activity. F-actin (2 mM) was incubated with different meta- (H17009),
decavanadate () and vanadyl sulfate () concentrations for 20 min at 25 ◦C. The capacity to stimulate S1 ATPase (0.05 mg ml-1) activity was monitored
by coupled enzymes assay and followed at 340 nm as indicated in the Experimental section. Data (solid squares, triangles and circles) are plotted as
means ± SD. The results shown are the average of triplicate experiments.
F-actin, full oxidation of the “fast cysteine” was observed,
along with the oxidation of the core cysteine mentioned above,
with IC50 values for vanadate-induced oxidation of exposed and
total F-actin cysteines of 11.2 ± 0.1 and 20.9 ± 0.2 mM of
decavanadate (1.1 and 2.1 mM V10), respectively (Fig. 6B and
C). The Cys-374 oxidation upon decavanadate exposure may
explain, at least in part, the observed blockage of myosin ATPase
activity stimulation. Moreover, the oxidation of this residue
may be involved in the F-actin depolymerization, as described
elsewhere.35,36 Recently, it was pointed out that decavanadate
prevents G-actin polymerization with an IC50 of 17 mM.3 Once
F-actin only promotes myosin ATPase stimulation, it is suggested
that the effects promoted by decavanadate may involve changes in
the structure of actin that alters the polymerization and the depoly-
merization process and therefore the stimulation of the enzyme
activity.
When the incubation of decavanadate with actin was monitored
by EPR, the addition of the decameric ion to the protein
(25:1 decavanadate:protein ratio) elicited the appearance of a
typical eight-band electron spin resonance spectrum assigned
to oxidovanadium(IV), indicating vanadate reduction, probably
through the above-mentioned reaction with sulfydryl groups of
the protein (Fig. 7). Following the different G- and F-actin
patterns for cysteine oxidation upon decavanadate incubation, the
spectra demonstrate that signiﬁcant differences exist between the
localmetal coordination environments for the oxidovanadium(IV)
cation (Figs. 7B and C). Previously, the reaction of vanadate
with thiol groups of fructose-1,6-bisphophate aldolase,37 and
glyceraldehyde-3-P dehydrogenase was also described.38 On the
other hand, it was noted that isocitrate dehydrogenase has the
ability to reduce decavanadate.39 Although the presence of ﬁve
cysteines in actin does not necessarily imply redox chemistry
with vanadate,40 as was observed above, at speciﬁc protein
conformation, that is when the actin is in the F-actin state, Cys-374
may react with vanadate, and be oxidized.
3.4 Vanadyl interactions with actin
The uptake of vanadate (+5) by cells, namely erythrocytes,41
fat cells42 and yeast,43 is preceded by the rate-limiting reduction
step to oxidovanadium(IV) ion, complexed with glutathione
or proteins.38,40 Vanadate is also reduced in the presence of
cysteines, generating cystine and oxidovanadium(IV),44 with the
sixth position of oxovanadium occupied by either carboxylate-
oxygen of two cysteine molecules.11
Although it was observed that the oxidovanadium(IV) cation
only promotes a minor effect in F-actin-stimulated S1-ATPase
activity, a parallel V(IV)-actin binding study was carried out
by EPR at 77 K, in order to reduce molecular motion. As can
be observed in Fig. 8A, the addition of 250 mM VOSO4 to the
reaction medium (2 mM Tris, 0.2 mM CaCl2) did not promote
the appearance of typical oxidovanadium(IV) signals. In fact,
for V(IV) species, at physiological pH and in a non-complexing
media, no EPR signal can be observed. For higher buffer
concentrations13 it was observed that Tris interacts fairly strongly
with the oxidovanadium(IV) cation (20 mM Tris and 0.001 M
VO2+). Thus the observation of an EPR spectrum at neutral
pH would indicate that either a complexing ligand is present in
solution or that the pH is no longer neutral.5,45 Since no alterations
in pH value (7.5) were observed subsequent to oxidovanadium(IV)
addition to the reaction mixture, immediately before samples were
frozen with liquid nitrogen, the signals observed upon G- and
F-actin addition (50 and 30 mM, respectively) can only be attri-
buted to a metal–protein interaction (Fig. 8B and C, respectively).
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Fig. 6 G- (A) and F-actin (B, C) cysteine oxidation upon treatment
of actin with decavanadate. Titration of cysteines was performed with
0.1 mM DTNB and 2 mM actin in 2 mM Tris (pH 7.5), 0.2 mM
CaCl2 (G-actin) and 0.2 mM ATP (F-actin). The increase in absorbance
at 412 nm was continuously recorded over 10 min; to measure total
cysteines the samples were treated afterwards with 1% SDS and the
absorbance was measured over 15–30 min until a steady value was
reached. (A) Treatment with decavanadate produced a dose-dependent
decrease of G-actin total cysteines () while Cys-374 remained in the
reduced form (H17009). (B) Treatment with decavanadate produced a complete
dose-dependent decrease of exposed F-actin cysteine (H17009). (C) Treatment
with decavanadate produced a dose-dependent decrease of total F-actin
cysteines (). Data (solid squares and triangles) are plotted as means ±
SD. The results shown are the average of triplicate experiments.
Fig. 7 Frozen aqueous solution X-band EPR spectra of 25 mM
decavanadate (vanadate total) in (A) 2 mM Tris (pH 7.5), 0.2 mM CaCl2,
0.2 mM ATP with (B) 100 mM G-actin or (C) 100 mM F-actin. Upon
protein addition the oxidovanadium(IV) typical signals are elicited.
Fig. 8 Frozen aqueous solution X-band EPR spectra of 250 mM VOSO4
in (A) 2 mM Tris (pH 7.5), 0.2 mM CaCl2, with (B) 50 mM G-actin, (C)
30 mM F-actin, (D) 0.2 mM ATP and (E) 50 mM G-actin plus 0.2 mM
ATP.
Therefore, the absolute intensity of the vanadium EPR signals can
be correlated upon titration of oxidovanadium(IV) with protein.46
Upon ATP addition, a complex between oxidovanadium(IV)
cation and nucleotide occurs47 (Fig. 8D); thus when the buffer
assay contains ATP (2 mM Tris, 0.2 mM CaCl2, 0.2 mM ATP)
the VO2+–ATP complex can be observed in the EPR spectra.
Moreover, it was observed that the presence of ATP in the
medium prevents the interaction between oxidovanadium(IV) ion
and G-actin, since the EPR signals almost disappear, being less
intense when the nucleotide is concomitantly added to the assay
(Fig. 8E). Although all the samples were prepared in the same
conditions in the glove chamber, the reduction of the EPR signal,
in the case of paramagnetic ions, could be due to either spin–spin
interactions between the VO2+ and the added nucleotide or from
the displacement of VO2+ from the protein. The reduction of the
EPR intensity could also arise from partial metal ion re-oxidation.
Based on the experimental hyperﬁne constant, A‖, it is possible
to predict the contribution of the donors to this value, that is, the
nuclei to which the unpaired electrons are coupled. However, as
the typical A‖ values obtained by simulation varies between 31.9 ¥
10-4 and 45.7 ¥ 10-4 cm-1, with the generally accepted error being
ca. ± 1.5 ¥ 10-4, the use of the additivity relationship introduces
a caveat since there is often more than one combination of
ligands which can, within the error limits, give the experimentally
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determined A‖. Therefore, more than one combination of donors,
can give the observed value (195.6 G), the possibility of a
species of three water molecules and one carboxylate (Asp or
Glu), or one imidazole (His) or of species with two waters
and two imidazoles (or their combination) must be taken into
account. As a consequence, the knowledge of the possible ligand
types in the protein (or in any other molecules) structure is of
primary importance.48 As a simulation spectrum of the interaction
between oxidovanadium(IV) and F-actin presents A‖ = 195.6 G =
531.0798 MHz, A^ = 65 G, g^ = 1.998 and g‖ = 1.9399 (Fig. 9,
top), it is suggested that the oxidovanadium(IV) ion is coordinated
to the oxygen of three watermolecules and one equatorial nitrogen
of an amine group present in the lateral amino acid residue chain
such as asparagine (Asn), glutamine (Gln) or lysine (Lys), taking
into account the A‖ and the g‖ values obtained and the table of
the equatorial vanadyl ligands from Chasteen.49 Since it is known
that Lys-336 is close to the nucleotide ring in the tertiary structure
of actin,50 the above results with ATP and G-actin indicate that
the oxidovanadium(IV) ion may be bound to the nitrogen of the
Lys-336’s side chain. When actin is in its polymerized form the
nucleotide binding pocket is eventually blocked and ATP presence
does not alter the V(IV)–F-actin spectrum.
Fig. 9 Frozen aqueous solution X-band EPR spectra of VO–actin.
VOSO4 concentration was 250 mM. The protein concentrations were (A)
30 mM F-actin, in 2 mM Tris (pH 7.5), 0.2 mM CaCl2, 0.2 mM ATP;
and (B) 50 mM G-actin, in 2 mM Tris (pH 7.5), 0.2 mM CaCl2. The
bottom traces in (A) and (B) are the spectra in the absence of protein. The
middle spectra are the experimental spectra of the preparations with actin
added. The top spectra are the corresponding spectra simulation with the
EPR parameters given in the text. For the simulation of EPR spectra
the linewidths for G-actin, were 20.0, 20.0, and 24.0 G, respectively for the
x-direction, y-direction and z-direction whereas for F-actin: 22.2, 22.2 and
26.6 G were used. The lineshapes were Lorentzian/Gaussian for both.
The extent of VO2+ binding to actin was measured from the
mi = -1/2 perpendicular line, (Fig. 9), since this band exhibits the
major intensity and the best linearity when oxidovanadium(IV)
(250 mM) is titrated with actin (data not shown). The intensity of
this band was plotted against oxidovanadium(IV) concentration
(mM) and a Kd of 7.48 ± 1.11 mM G-actin and 43.05 ± 5.34 mM
F-actin (Fig. 10A and B) was calculated. From the data collected
in latter plots, it was determined that aproximately 1 and 4 VO2+
ions are bound per G- and F-actin molecule, respectively. Other
studies performed with ferritin described a stoichiometry of 16
VO2+ per protein.45 Therefore, the observed decrease in EPR signal
intensities of the VO2+–G-actin spectrum by comparison with
VO2+–F-actin, can be explained by the VO2+ cation bound to the
monomeric state of the protein.
Fig. 10 EPR intensities from the transition peakmi = -1/2 perpendicular
line of 250mMVOSO4 titratedwith different concentrations of (A)G-actin,
in 2 mM Tris (pH 7.5), 0.2 mM CaCl2; and (B) F-actin, in 2 mM Tris
(pH 7.5), 0.2 mM CaCl2, 0.2 mM ATP. Data (solid squares) are plotted as
means ± SD. The results shown are the average of triplicate experiments.
Since oxidovanadium(IV) has little effect on the S1-ATPase
activity stimulated byF-actin, although strong evidence of binding
to actin have been observed, it could be predicted that oxidovana-
dium(IV) binds to actin in places that do not signiﬁcantly alter
the actin conformation and its ability to interact with the myosin-
subfragment-1.
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4. Conclusions
Knowledge of mechanisms of action of vanadium in processes
that involve actin is scarce or nonexistent. So far, in cells, vanadate
is known to stabilize F-actin ﬁlaments through the formation
of F-actin-ADP·V1 complexes and induces actin polymerization
by inhibiting speciﬁc tyrosine phosphatases, whereas in vitro,
decavanadate is particularly involved in the inhibition of both
actin polymerization and myosin ATPase activity. In the present
paper, it is suggested that decavanadate interaction with F-actin
induces oxidation of cysteine through a process that involves the
reduction of vanadate to oxidovanadium(IV). It is proposed that
changes in protein structure due to cysteine oxidation may be
responsible, at least in part, for the inhibition of myosin ATPase
activity stimulated by F-actin.
It was concluded that the decomposition of V10 follows a ﬁrst
order kinetic in a temperature-dependent manner and with an
Ea of 63.4 ± 2.7 kJ mol-1.1 Using NMR spectroscopy, it was
possible to analyze the vanadate species and the composition
of the vanadate solutions at several experimental conditions,
as well as the speciﬁc interactions of the different vanadate
oligomers with the protein. It was observed that interaction of
actin with V10, as analysed by the broadening of the V10A NMR
signal, decreases upon increasing ionic strength and increases in
the presence of high concentrations of ATP, a natural ligand of the
protein. The broadening factor of V10A NMR signal increases as a
sigmoid function upon increasing G-actin concentration whereas
no similar pattern was observed upon titration with F-actin. For
G-actin, a 2.5 mM concentration of V10 species is enough to
produce 50% of the broadening effect. By comparison to vanadate
or oxidovanadium(IV), decavanadate inhibits strongly the myosin
ATPase activity stimulated by F-actin, with an IC50 of 0.8 mM V10
species. Decavanadate, but not metavanadate, incubation with F-
actin induces Cys-374 oxidation, the so called “fast cysteine”,
with a IC50 of 1 mM V10 species besides the oxidation of a core
cysteine, whereas for G-actin only the latter effect is observed.
Actin exposure to decavanadate promotes vanadate reduction,
since a typical EPR signal is detected. Following V10 reduction
to oxidovanadium(IV), it is suggested that the cation may form a
complexwithG-actin andF-actinwith 1:1 and 4:1 stoichiometries,
respectively. The interaction of oxidovanadium(IV) ion may occur
close to the ATP binding site since our observations suggest
coordination to Lys-336 and 3 water molecules. Although further
studies will be needed, it is believed that the present data will
contribute to the understanding of the role of vanadium in
biochemical processes where actin is present.
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